Skip to main content

Table 1 Baseline demographic and clinical data of the 1/2PDT and 1/3PDT group

From: Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy

 

1/2group

1/3group

P value

Age

51.5 ± 5.7

46.3 ± 7.2

0.04

sex (male:female)

9:03

12:03

0.78

BCVA (logMAR BCVA)

0.13 ± 0.25

0.21 ± 0.25

0.35

duration of symptoms (months)

16.8 ± 12.2

18.5 ± 16.4

0.59

IOP (mmHg)

15.0 ± 1.8

13.5 ± 3.7

0.06

OPP (mmHg)

51.3 ± 7.5

52.3 ± 12.6

0.90

CCT (μm)

334.2 ± 94.5

275.1. ± 94.5

0.67

CRT (μm)

451.2 ± 132.5

452.2 ± 85.1

0.88

PDT spot size (μm)

2888.3 ± 550.5

2558.9 ± 710.7

0.22

  1. BCVA best-corrected visual acuity, IOP intraocular pressure, OPP ocular perfusion pressure, CRT central retinal thickness, CCT central choroidal thickness, 1/2PDT half-dose photodynamic therapy, 1/3PDT one-third dose photodynamic therapy, logMAR logarithm of the minimum angle of resolution.
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us